150 related articles for article (PubMed ID: 38229760)
1. MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3.
Smalley JP; Cowley SM; Hodgkinson JT
ACS Med Chem Lett; 2024 Jan; 15(1):93-98. PubMed ID: 38229760
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.
Smalley JP; Baker IM; Pytel WA; Lin LY; Bowman KJ; Schwabe JWR; Cowley SM; Hodgkinson JT
J Med Chem; 2022 Apr; 65(7):5642-5659. PubMed ID: 35293758
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation.
Dovey OM; Foster CT; Cowley SM
Proc Natl Acad Sci U S A; 2010 May; 107(18):8242-7. PubMed ID: 20404188
[TBL] [Abstract][Full Text] [Related]
4. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase CK2 regulates the dimerization of histone deacetylase 1 (HDAC1) and HDAC2 during mitosis.
Khan DH; He S; Yu J; Winter S; Cao W; Seiser C; Davie JR
J Biol Chem; 2013 Jun; 288(23):16518-16528. PubMed ID: 23612983
[TBL] [Abstract][Full Text] [Related]
6. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
9. Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.
Thomas EA
Pharmaceuticals (Basel); 2014 May; 7(6):634-61. PubMed ID: 24865773
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
[TBL] [Abstract][Full Text] [Related]
11. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
Han X; Wei W; Sun Y
Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
[TBL] [Abstract][Full Text] [Related]
12. MDM2 accelerated renal senescence via ubiquitination and degradation of HDAC1.
Xiang HL; Yuan Q; Zeng JY; Xu ZY; Zhang HZ; Huang J; Song AN; Xiong J; Zhang C
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38760541
[TBL] [Abstract][Full Text] [Related]
13. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
Ashburner BP; Westerheide SD; Baldwin AS
Mol Cell Biol; 2001 Oct; 21(20):7065-77. PubMed ID: 11564889
[TBL] [Abstract][Full Text] [Related]
14. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
15. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
Zahid S; Ali Y; Rashid S
J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
[TBL] [Abstract][Full Text] [Related]
16. Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.
Heideman MR; Lancini C; Proost N; Yanover E; Jacobs H; Dannenberg JH
Haematologica; 2014 Aug; 99(8):1292-303. PubMed ID: 24763403
[TBL] [Abstract][Full Text] [Related]
17. CaMKII exacerbates heart failure progression by activating class I HDACs.
Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
19. MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification.
Kwon DH; Eom GH; Ko JH; Shin S; Joung H; Choe N; Nam YS; Min HK; Kook T; Yoon S; Kang W; Kim YS; Kim HS; Choi H; Koh JT; Kim N; Ahn Y; Cho HJ; Lee IK; Park DH; Suk K; Seo SB; Wissing ER; Mendrysa SM; Nam KI; Kook H
Nat Commun; 2016 Feb; 7():10492. PubMed ID: 26832969
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase-3 complex contains nuclear receptor corepressors.
Wen YD; Perissi V; Staszewski LM; Yang WM; Krones A; Glass CK; Rosenfeld MG; Seto E
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7202-7. PubMed ID: 10860984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
